MMIRF (MedMira) Notes Receivable: $0.00 Mil (As of Jan. 2026)


What is MedMira Notes Receivable?

MedMira MMIRF +302.48% Notes Receivable is $0.00 Mil as of Jan. 2026. The stock has 6 warning signs investors should review.

MedMira's Notes Receivable for the quarter that ended in Jan. 2026 was $0.00 Mil.

MedMira Notes Receivable Historical Data

* Premium members only.

The historical data trend for MedMira's Notes Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

MedMira Notes Receivable Chart

MedMira Annual Data
Trend Jul16 Jul17 Jul18 Jul19 Jul20 Jul21 Jul22 Jul23 Jul24 Jul25
Notes Receivable
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

MedMira Quarterly Data
Apr21 Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24 Apr24 Jul24 Oct24 Jan25 Apr25 Jul25 Oct25 Jan26
Notes Receivable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

MedMira Notes Receivable Calculation

Notes Receivable is an unconditional promise to receive a definite sum of money at a future date(s) within one year of the balance sheet date or the normal operating cycle, whichever is longer.

Frequently Asked Questions Learn more about Notes Receivable →
What does a Notes Receivable of $0.00 Mil mean?
MedMira (MMIRF) has a Notes Receivable of $0.00 Mil as of Jan. 2026. Notes Receivable is an unconditional promise to receive a definite sum of money within one year. View historical data on MedMira and its competitors.
Is MedMira's Notes Receivable too high?
MedMira's current Notes Receivable is $0.00 Mil.
How does MedMira's Notes Receivable compare to VRTX and REGN?
MedMira's Notes Receivable of $0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Notes Receivable for a Biotechnology company?
A good Notes Receivable depends on the Biotechnology industry context. However, Notes Receivable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Notes Receivable mean?
A high Notes Receivable can signal that a stock is expensive relative to its fundamentals. Notes Receivable is an unconditional promise to receive a definite sum of money within one year. View historical data on MedMira and its competitors. MedMira's current Notes Receivable is $0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is MedMira stock overvalued right now?
MedMira (MMIRF) has a current Notes Receivable of $0.00 Mil. The current Notes Receivable is $0.00 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Notes Receivable calculated?
Notes Receivable is calculated from a company's financial statements. For MedMira (MMIRF), the current Notes Receivable is $0.00 Mil as of Jan. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

MedMira Business Description

Other Exchanges MIR:Canada
Address 155 Chain Lake Drive, Suite 1, Halifax, NS, CAN, B3S 1B3
MedMira Inc is a biotechnology company engaged in the research, development, and manufacturing of rapid diagnostics and technologies. The company operates in one reportable operating segment, rapid diagnostic products and services. Its product line includes HIV, COVID-19, syphilis, Multiplex, Miriad RVF Toolkit, and H. pylori. The company generates revenue from North America, Europe, and other regions, with the majority generated from North America.